Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide and ADT in High-Risk Prostate Cancer Post-Radical Prostatectomy
NCT04523207Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide in prostate cancer (PCa), sponsored by Janssen Pharmaceutical. Started Aug 2020; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04523207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523207.